Grown Rogue International (GRUSF) Total Non-Current Liabilities (2009 - 2026)
Grown Rogue International (GRUSF) posted quarterly Total Non-Current Liabilities of $2.9 million for Q1 2026, down 89.49% year-over-year from $27.7 million in Q1 2025, and down 3.0% quarter-over-quarter from $3.0 million in Q4 2025.
Grown Rogue International (GRUSF) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Grown Rogue International's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 89.49% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 89.49% YoY), while the FY2025 annual figure was $3.0 million, down 51.78% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $2.9 million, down from $3.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $23005.2 billion in Q3 2025, with the low at -$279839.7 in Q2 2025.
- The 5-year median for Total Non-Current Liabilities is $3.0 million (2025), against an average of $2300.5 billion.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities plunged 134.47% in 2024, then jumped 1652.92% in 2025.
- Grown Rogue International's Total Non-Current Liabilities stood at $5.3 million in 2022, then sank by 89.47% to $560425.0 in 2023, then slumped by 134.47% to -$193195.5 in 2024, then surged by 1652.92% to $3.0 million in 2025, then fell by 3.0% to $2.9 million in 2026.
- Business Quant data shows GRUSF's Total Non-Current Liabilities at $2.9 million in Q1 2026, $3.0 million in Q4 2025, and $23005.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Grown Rogue International | 109.32 Mn | 97.78 Mn | 5.37 Mn | 2.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.68 Mn |
| Mar 31, 2026 | 2.91 Mn |
| Dec 31, 2025 | 3.00 Mn |
| Sep 30, 2025 | 23,005.21 Bn |
| Jun 30, 2025 | -279,839.69 |
| Mar 31, 2025 | 27.68 Mn |
| Dec 31, 2024 | -193,195.51 |
| Dec 31, 2023 | 560,425.00 |
| Oct 31, 2023 | 253,340.00 |
| Jul 31, 2023 | 11.56 Mn |
| Oct 31, 2022 | 5.32 Mn |
| Oct 31, 2021 | 1.23 Mn |
| Oct 31, 2020 | 68,994.00 |
| Aug 31, 2018 | 63,212.58 |
| May 31, 2018 | -572,977.84 |
| Feb 28, 2018 | -573,520.90 |
| Nov 30, 2017 | -558,401.76 |
| Aug 31, 2017 | -170,845.96 |
| May 31, 2017 | -2.10 Mn |
| Feb 28, 2017 | -2.13 Mn |